Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated?

导出原文传递

翻译打印收藏纠错

第一作者： Minhua,Wang

第一单位： Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

作者： Minhua,Wang ^[1] ; Qingqing,Ding ^[1] ; Jun,Gu ^[2] ; Steven M,Sfamenos ^[2] ; Lei,Huo ^[1] ; Zhenya,Tang ^[3] ; Hongxia,Sun ^[1] ; Melissa,Robinson ^[3] ; Guilin,Tang ^[3] ; Bora,Lim ^[4] ; Yun,Wu ^[1] ; Constance T,Albarracin ^[1] ; Aysegul A,Sahin ^[1] ; Hui,Chen ^[5]

作者单位： Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[1] The University of Texas MD Anderson Cancer Center, School of Health Professions, Houston, TX. ^[2] Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[3] Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[4] Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: hchen7@mdanderson.org. ^[5]

关键词 ASCO/CAP guidelines FISH HER2 amplification Monosomy CEP17 heterogeneity

主题词人类(Humans);女(雌)性(Female);乳腺肿瘤(Breast Neoplasms);原位杂交, 荧光(In Situ Hybridization, Fluorescence);回顾性研究(Retrospective Studies);Ki-67抗原(Ki-67 Antigen);肿瘤复发, 局部(Neoplasm Recurrence, Local)

DOI 10.1016/j.clbc.2023.02.006

PMID 36878823

发布时间 2023-06-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交